Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis
المؤلفون المشاركون
Lin, Yiguang
Wu, Di
Chen, Tiejun
Jiang, Han
Duan, Chongyang
Zhang, Xinjian
Chen, Size
Wu, Fenfang
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-03-19
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
This network meta-analysis addresses the need for evidence-based best-practice treatment regimens for HER2-positive breast cancer.
We compared the relative efficacy and tolerability of currently available HER2-positive neoadjuvant immunotherapy regimens based on systematic searches of available randomized controlled trials (RCTs) data.
Based on intention-to-treat principle, pathological complete response (pCR), overall serious adverse events (SAEs), and breast-conserving surgery (BCS) rate were analyzed using random-effect, Bayesian network meta-analysis, and standard pairwise meta-analysis.
16 RCTs (3868 patients) were included.
Analyzed treatment regimens were as follows: chemotherapy+trastuzumab+pertuzumab (CTP), trastuzumab emtansine+pertuzumab (MP), chemotherapy+trastuzumab (CT), chemotherapy+pertuzumab (CP), trastuzumab+pertuzumab (TP), chemotherapy+trastuzumab+lapatinib (CTL), and chemotherapy+lapatinib (CL), and chemotherapy (C) alone.
We found that, for the chance of achieving pCR, CTP was ranked first (SUCRA: 97%), followed by CTL, MP, and CT (SUCRA: 80%, 75%, and 55%, resp.).
MP provided the safest regimen (SUCRA: 97%), then TP, C, and TPC (SUCRA: 82%, 76%, and 47%, resp.).
CTL proved the most toxic therapy (SUCRA: 7%).
No significant difference between neoadjuvant regimens was identified for BCS.
Hormone receptor status did not impact ORs for pCR in any regimen.
In conclusion, our findings support CTP as the optimum neoadjuvant regimen for HER2-positive breast cancer, with the best pCR and acceptable toxicity compared with CT.
MP provides a therapeutic option for patients with poor performance status.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wu, Di& Chen, Tiejun& Jiang, Han& Duan, Chongyang& Zhang, Xinjian& Lin, Yiguang…[et al.]. 2019. Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis. Journal of Oncology،Vol. 2019, no. 2019, pp.1-14.
https://search.emarefa.net/detail/BIM-1184130
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wu, Di…[et al.]. Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis. Journal of Oncology No. 2019 (2019), pp.1-14.
https://search.emarefa.net/detail/BIM-1184130
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wu, Di& Chen, Tiejun& Jiang, Han& Duan, Chongyang& Zhang, Xinjian& Lin, Yiguang…[et al.]. Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis. Journal of Oncology. 2019. Vol. 2019, no. 2019, pp.1-14.
https://search.emarefa.net/detail/BIM-1184130
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1184130
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر